Emergex Vaccines Holding Limited

Immunotope, Inc.

Emergex Vaccines Holdings Limited

Philip, Ramila

Ramila Philip

Venky Ramakrishna

Mark M Ross

Thomas Rademacher

Lorraine Keller

Christopher Upton

Laurens Rademacher

Richard David Perrins

Xiaofang Huang

The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD+ T cell epitopes, wherein the peptide is attached to a nanoparticle.

Vaccine compositions

The invention provides a vaccine composition comprising a flavi peptide comprising one or more CD8+ T cell epitopes.

MHC class i associated peptides for prevention and treatment of multiple flavi virus

The invention relates to vaccine compositions comprising peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a ssRNA virus in the opposite sense to positive sense RNA capable of translation, and the use of such compositions for the treatment and prevention of viral infection.

Reverse peptide vaccine

The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle.

MHC class I associated peptides for prevention and treatment of zika virus

MHC class I associated peptides for prevention and treatment of multiple flavi virus

The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell C1 epitopes, wherein the peptide is attached to a nanoparticle.

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHF) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. Herein, we report novel, naturally processed and presented MHC class I restricted epitopes, a subset of which binds to and activates T cells in both an HLA-A2 and HLA-A24 restricted manner. We show that epitope specific T cells can be activated in vivo in transgenic mice and in vitro in seropositive and seronegative individuals and that these T cells are functional, recognizing peptide pulsed and dengue virus infected cells in a pro-inflammatory and cytotoxic manner. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and may serve as a universal vaccine candidate complementary to current vaccines in trial.

Pharmaceutical compositions comprising dengue virus-specific multiple HLA-binding T cell epitopes

The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.

Universal influenza vaccine compositions

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of Hepatitis B virus (HBV) infection, and discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against HBV infection. The peptide and/or proteins of the invention may be used as a therapeutic drug to stimulate the immune system to recognize and eliminate HBV infection in infected cells or as a vaccine for the prevention of disease.

MHC class I associated hepatitis B peptides

Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.

Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.

Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer

MHC class I associated peptides for prevention and treatment of hepatitis B virus infection

Cytotoxic T Lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection

Dengue virus specific multiple HLA binding T cell epitopes for the use of universal vaccine development

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as lung carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against lung and other cancers.

Growing community of inventors

Ivyland, PA, United States of America

Ramila Philip